Lung Cancer Clinical Trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Summary

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To compare investigator-assessed progression-free survival (IA-PFS) between participants with EGFR mutated, MET amplified non-small cell lung cancer (NSCLC) randomized to INC280 (capmatinib) and osimertinib with or without ramucirumab.

SECONDARY OBJECTIVES:

I. To evaluate if the combination of INC280 (capmatinib), osimertinib and ramucirumab or INC280 (capmatinib) and osimertinib during the first cycle of treatment has an acceptable toxicity rate.

II. To evaluate the frequency and severity of toxicities within the arms. III. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification in tissue.

IV. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification based on circulating tumor deoxyribonucleic acid (ctDNA).

V. To compare IA-PFS between the randomized arms in the subsets of participants with and without history of brain metastases.

VI. To compare the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) between the arms among participants with measurable disease at baseline.

VII. To compare overall survival between the arms. VIII. To compare IA-PFS between the randomized arms in the subsets of patients who have received only 1 prior line of therapy and those who have received 2 or more prior lines of therapy.

IX. To evaluate duration of response among responders within each arm.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To collect, process, and bank cell-free deoxyribonucleic acid (ctDNA) prior to treatment (Cycle 1 Day 1), Cycle 1 Day 15, Cycle 3 Day 1, and first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA).

II. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive capmatinib orally (PO), osimertinib PO, and ramucirumab intravenously (IV) on study. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.

ARM B: Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Participants must have been assigned to S1900G by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900G is determined by the LUNGMAP protocol
Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physician) on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy. Any number of prior lines of therapy is allowed

Participants must have a MET amplification determined by tissue-based or blood-based (circulating tumor DNA [ctDNA]) next generation sequencing (NGS) assay. MET amplifications may have been determined based on tissue submitted for testing by Foundation Medicine Inc (FMI) through the LUNGMAP screening protocol or using test results completed outside of the study. Tissue or blood must be obtained after disease progression on osimertinib (alone or in combination with another agent[s]). The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)/Independent Ethics Committee (IEC), College of American Pathologists (CAP), or similar certification

Note: Participants previously tested for and determined to have MET amplified NSCLC, at the time of progression on osimertinib, outside of LUNGMAP, must also submit tissue for central FMI testing on the LUNGMAP screening protocol, if available
Participants must have either measurable disease or non-measurable disease documented by CT or MRI. The CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to sub-study randomization. Non-measurable disease must be assessed within 42 days prior to sub-study randomization. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study randomization to be considered measurable
Participants must have a CT with contrast or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study randomization
Participants with symptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be neurologically stable and have a stable or decreasing corticosteroid requirement for at least 5 days before sub-study randomization
Participants must have recovered (=< grade 1) from any side effects of prior therapy, except for alopecia and vitiligo
Participants must be able to swallow tablets whole
Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to sub-study randomization)
Hemoglobin < 9.0 g/dL (within 28 days prior to sub-study randomization)
Platelets >= 100 x 10^3/uL (within 28 days prior to sub-study randomization)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to sub-study randomization). Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN. Participants with history of liver metastasis must have AST =< 5 x ULN (within 28 days prior to sub-study randomization)
Participants must have a serum creatinine =< the IULN OR calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization
Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization
Participants must have an electrocardiogram (ECG) performed, with a Fridericia's Correction Formula (QTcF) =< 470 msec, within 28 days prior to sub-study randomization. It is suggested that a local cardiologist review the QTcF intervals
Participants must have a completed medical history and physical exam within 28 days prior to sub-study randomization
Participants must have a urinalysis performed 28 days prior to sub-study randomization. Participant must have a urinary protein =< 1+ on dipstick or routine urinalysis (UA). Random analysis of urine protein with a normal value is sufficient. If urine dipstick or routine analysis indicated proteinuria >= 2+, then a 24-hour urine is to be collected and demonstrate < 2000 mg of protein in 24 hours to allow participation in the study
Participants must have an International Normalized Ratio (INR) =< 1.5 seconds above the institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days to sub-study randomization. Participants must have a partial thromboplastin time (PTT) =< 5 seconds above the 'institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days prior to sub-study randomization
Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load within 6 months prior to sub-study randomization
Participants must have asymptomatic serum amylase =< 2 x ULN and serum lipase =< ULN obtained within 28 days prior to sub-study randomization. Asymptomatic is defined as having no signs and/ or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P. amylase, abnormal imaging findings of pancreas, etc.)
Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA)
Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Participants with impaired decision-making capacity must not have a neurological or psychological condition that precludes their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator). For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Exclusion Criteria:

Participants must not have received an anti-VEGF or VEGFR inhibitor or MET inhibitor

Participants must not have received any anti-cancer drug (investigational or standard of care drug, except osimertinib) within 21 days prior to sub-study randomization

Note: osimertinib may continue up to the day prior to study treatment initiation
Participants must not have received any radiation therapy within 14 days prior to sub-study randomization
Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
Participants must not have had a major surgery within 14 days prior to sub-study randomization. Participants must have fully recovered from the effects of prior surgery in the opinion of the treating investigator
Participants must not have received a live attenuated vaccination within 28 days prior to sub-study randomization. All COVID-19 vaccines that have received Food and Drug Administration (FDA) approval or FDA emergency use authorization are acceptable
Participants must not have received strong inducers of CYP3A4 (including herbal supplements such as St. John's Wort); CYP3A4 inhibitors; CYP1A2 substrates; P-gp and BCRP substrates; sensitive substrates of MATE1 and MATE2K; or drugs that are known to prolong QT interval within 7 days prior to sub-study registration and must not be planning to use any of these throughout protocol treatment
Participants must not have uncontrolled blood pressure and hypertension within 28 days prior to sub-study randomization
Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

66

Study ID:

NCT05642572

Recruitment Status:

Recruiting

Sponsor:

SWOG Cancer Research Network

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 68 Locations for this study

See Locations Near You

Cancer Center at Saint Joseph's
Phoenix Arizona, 85004, United States
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande California, 93420, United States
Mercy Cancer Center �� Carmichael
Carmichael California, 95608, United States
Mercy San Juan Medical Center
Carmichael California, 95608, United States
Mercy Cancer Center - Elk Grove
Elk Grove California, 95758, United States
Memorial Medical Center
Modesto California, 95355, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Palo Alto Medical Foundation Health Care
Palo Alto California, 94301, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Mercy Cancer Center - Rocklin
Rocklin California, 95765, United States
Mercy Cancer Center - Sacramento
Sacramento California, 95816, United States
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo California, 93401, United States
Mission Hope Medical Oncology - Santa Maria
Santa Maria California, 93444, United States
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale California, 94086, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Woodland Memorial Hospital
Woodland California, 95695, United States
Penrose-Saint Francis Healthcare
Colorado Springs Colorado, 80907, United States
Rocky Mountain Cancer Centers-Penrose
Colorado Springs Colorado, 80907, United States
Saint Francis Cancer Center
Colorado Springs Colorado, 80923, United States
Porter Adventist Hospital
Denver Colorado, 80210, United States
Mercy Medical Center
Durango Colorado, 81301, United States
Southwest Oncology PC
Durango Colorado, 81301, United States
Saint Anthony Hospital
Lakewood Colorado, 80228, United States
Littleton Adventist Hospital
Littleton Colorado, 80122, United States
Longmont United Hospital
Longmont Colorado, 80501, United States
Parker Adventist Hospital
Parker Colorado, 80138, United States
Saint Mary Corwin Medical Center
Pueblo Colorado, 81004, United States
Northeast Georgia Medical Center-Gainesville
Gainesville Georgia, 30501, United States More Info
Site Public Contact
Contact
770-219-8800
[email protected]
Charles H. Nash
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Canton
Canton Illinois, 61520, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States More Info
Site Public Contact
Contact
815-285-7800
Bryan A. Faller
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peru
Peru Illinois, 61354, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Alegent Health Mercy Hospital
Council Bluffs Iowa, 51503, United States
Flaget Memorial Hospital
Bardstown Kentucky, 40004, United States
Commonwealth Cancer Center-Corbin
Corbin Kentucky, 40701, United States
Saint Joseph Hospital
Lexington Kentucky, 40504, United States
Saint Joseph Radiation Oncology Resource Center
Lexington Kentucky, 40504, United States
Saint Joseph Hospital East
Lexington Kentucky, 40509, United States
Saint Joseph London
London Kentucky, 40741, United States
Saint Joseph Mount Sterling
Mount Sterling Kentucky, 40353, United States
Lafayette Family Cancer Center-EMMC
Brewer Maine, 04412, United States More Info
Site Public Contact
Contact
800-987-3005
Sarah J. Sinclair
Principal Investigator
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
CHI Health Good Samaritan
Kearney Nebraska, 68847, United States
Saint Elizabeth Regional Medical Center
Lincoln Nebraska, 68510, United States
Alegent Health Immanuel Medical Center
Omaha Nebraska, 68122, United States
Alegent Health Bergan Mercy Medical Center
Omaha Nebraska, 68124, United States
Alegent Health Lakeside Hospital
Omaha Nebraska, 68130, United States
Creighton University Medical Center
Omaha Nebraska, 68131, United States
Midlands Community Hospital
Papillion Nebraska, 68046, United States
Virtua Samson Cancer Center
Moorestown New Jersey, 08057, United States More Info
Site Public Contact
Contact
856-247-7395
James W. Lee
Principal Investigator
Virtua Voorhees
Voorhees New Jersey, 08043, United States More Info
Site Public Contact
Contact
856-247-7395
James W. Lee
Principal Investigator
Good Samaritan Hospital - Cincinnati
Cincinnati Ohio, 45220, United States
Bethesda North Hospital
Cincinnati Ohio, 45242, United States
TriHealth Cancer Institute-Westside
Cincinnati Ohio, 45247, United States
TriHealth Cancer Institute-Anderson
Cincinnati Ohio, 45255, United States
ProMedica Flower Hospital
Sylvania Ohio, 43560, United States More Info
Site Public Contact
Contact
419-824-1842
[email protected]
Ahmed G. Elsayed
Principal Investigator
Langlade Hospital and Cancer Center
Antigo Wisconsin, 54409, United States More Info
Site Public Contact
Contact
715-623-9869
[email protected]
Andrew J. Huang
Principal Investigator
Aspirus Medford Hospital
Medford Wisconsin, 54451, United States More Info
Site Public Contact
Contact
715-847-2353
[email protected]
Andrew J. Huang
Principal Investigator
Ascension Saint Mary's Hospital
Rhinelander Wisconsin, 54501, United States More Info
Site Public Contact
Contact
715-847-2353
[email protected]
Andrew J. Huang
Principal Investigator
Ascension Saint Michael's Hospital
Stevens Point Wisconsin, 54481, United States More Info
Site Public Contact
Contact
715-847-2353
[email protected]
Andrew J. Huang
Principal Investigator
Aspirus Regional Cancer Center
Wausau Wisconsin, 54401, United States More Info
Site Public Contact
Contact
877-405-6866
Andrew J. Huang
Principal Investigator
Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids Wisconsin, 54494, United States More Info
Site Public Contact
Contact
715-422-7718
Andrew J. Huang
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

66

Study ID:

NCT05642572

Recruitment Status:

Recruiting

Sponsor:


SWOG Cancer Research Network

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.